Fitoussi Serge, Thang Carole, Lesauvage Eric, Barré Jérôme, Charron Brigitte, Filali-Ansary Aziz, Lameyre Valérie
Mediscis, Lagord, France.
Arzneimittelforschung. 2009;59(7):370-6. doi: 10.1055/s-0031-1296410.
To assess the effect of food on the pharmacokinetics of the anti-malarial amodiaquine (AQ, CAS 6398-98-7) and artesunate (AS, CAS 182824-33-5) and their active metabolites [desethylamodiaquine (DSA, CAS 81496-81-3) and dihydroartemisinin (DHA, CAS79352-78-6), respectively] in healthy volunteers.
In an open, two-way crossover study, 22 healthy male volunteers fasted overnight and were randomised to receive a single oral administration of 4 tablets of a fixed-dose combination containing 135 mg AQ and 50 mg AS in the absence or presence of a standardised high-fat breakfast, administered 30 min before drug administration. Blood samples were collected up to Day 10 and AQ, DSA, AS and DHA were assayed by an LC/MS/MS method.
Relative to the fasting state, the administration of the fixed-dose combination after a high-fat breakfast resulted in delayed median Tmax values for AQ (15 min and for DSA (2.3 h). The geometric mean ratios (GMR) of fed to fasting conditions indicated increased Cmax values for AQ (GMR 1.22) (90% CI: 1.07-1.39) and DSA (GMR 1.21) (90% CI: 1.05-1.39) and increased AUC0-t values for AQ (GMR 1.59) (90% CI: 1.39-1.83) and for DSA (GMR 1.13) (90% CI: 1.04-1.24). The median Tmax values were not delayed for AS as opposed to DHA (approximately 1 h delay). The Cmax values were decreased for AS (GMR 0.36) (90% CI: 0.30-0.47) and for DHA (GMR 0.51) (90% CI: 0.44-0.60). The AUC0-t values were slightly decreased for AS (GMR 0.89) (90% CI: 0.74-1.06) and for DHA (GMR 0.93) (90% CI: 0.84-1.02).
Intake of AQ and AS with a high fat meal resulted in (1) a statistically significant increase in blood levels of AQ and DSA which may affect the safety and tolerability of the study drugs and (2) a decrease in AS and DHA blood levels which may affect efficacy. These results suggest that the fixed-dose combination should not be administered with a high-fat meal.
评估食物对健康志愿者体内抗疟药阿莫地喹(AQ,化学物质登记号6398 - 98 - 7)和青蒿琥酯(AS,化学物质登记号182824 - 33 - 5)及其活性代谢产物[分别为去乙基阿莫地喹(DSA,化学物质登记号81496 - 81 - 3)和双氢青蒿素(DHA,化学物质登记号79352 - 78 - 6)]药代动力学的影响。
在一项开放、双向交叉研究中,22名健康男性志愿者隔夜禁食,随机分为两组,在服用含135 mg AQ和50 mg AS的固定剂量复方制剂前30分钟,一组在无标准化高脂早餐的情况下、另一组在有标准化高脂早餐的情况下接受单次口服给药。采集血样至第10天,采用液相色谱 - 串联质谱法测定AQ、DSA、AS和DHA。
与禁食状态相比,高脂早餐后服用固定剂量复方制剂导致AQ的中位达峰时间(Tmax)延迟(15分钟),DSA的中位达峰时间延迟(2.3小时)。进食与禁食条件下的几何平均比值(GMR)表明,AQ的血药峰浓度(Cmax)升高(GMR 1.22)(90%置信区间:1.07 - 1.39),DSA的血药峰浓度升高(GMR 1.21)(90%置信区间:1.05 - 1.39),AQ的药时曲线下面积(AUC0 - t)升高(GMR 1.59)(90%置信区间:1.39 - 1.83),DSA的药时曲线下面积升高(GMR 1.13)(90%置信区间:1.04 - 1.24)。与DHA相反,AS的中位达峰时间未延迟(DHA延迟约1小时)。AS的血药峰浓度降低(GMR 0.36)(90%置信区间:0.30 - 0.47),DHA的血药峰浓度降低(GMR 0.51)(90%置信区间:0.44 - 0.60)。AS的药时曲线下面积略有降低(GMR 0.89)(90%置信区间:0.74 - 1.06),DHA的药时曲线下面积略有降低(GMR 0.93)(90%置信区间:0.84 - 1.02)。
高脂餐时服用AQ和AS导致(1)AQ和DSA血药浓度有统计学意义的升高,这可能影响研究药物的安全性和耐受性;(2)AS和DHA血药浓度降低,这可能影响疗效。这些结果表明,固定剂量复方制剂不应与高脂餐同时服用。